Neuropsychotoxicity of abused drugs: Molecular and neural mechanisms of neuropsychotoxicity induced by methamphetamine, 3,4- methylenedioxymethamphetamine (ecstasy), and 5-methoxy-N,N-diisopropyltryptamine (foxy)

Journal of Pharmacological Sciences

Volumn 106, Issue 1, 2008, Pages 2-8

  Nakagawa, Takayuki ^a   Kaneko, Shuji ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

3,4 methylenedioxymethanphetamine (MDMA, "ecstasy"); 5 methoxy N,N diisopropyltryptamine (5 MeO DiPT, "foxy"); Dopaminergic glutamatergic system; Drugs of abuse; Methamphetamine; Serotonin transporter

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 5,7 DIHYDROXYTRYPTAMINE; CITALOPRAM; ECSTASY; FOXY; METHAMPHETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N,N DIISOPROPYL 5 METHOXYTRYPTAMINE; PSYCHOSTIMULANT AGENT; SEROTONIN UPTAKE INHIBITOR; TRITIUM; UNCLASSIFIED DRUG;

AUTONOMIC NERVOUS SYSTEM; CELL CULTURE; DOPAMINERGIC SYSTEM; DRUG ABUSE; DRUG MECHANISM; ELECTROPHYSIOLOGY; GLUTAMATERGIC SYSTEM; IN VITRO STUDY; LIMBIC SYSTEM; NERVE CONDUCTION; NEUROPSYCHOTOXICITY; NONHUMAN; OOCYTE; RAPHE NUCLEUS; SEROTONINERGIC SYSTEM; SHORT SURVEY; TOXICITY; XENOPUS;

EID: 38549167028     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.FM0070141     Document Type: Short Survey

References (34)

1. Nestler EJ. Molecular mechanisms of drug addiction. J Neurosci. 1992;12:2439-2450.
2. Rudnick G, Wall SC. The molecular mechanism of "ecstasy" [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci U S A. 1992;89:1817-1821.
3. White SR, Obradovic T, Imel KM, Wheaton MJ. The effects of methylenedioxymethamphetamine (MDMA, "Ecstasy") on monoaminergic neurotransmission in the central nervous system. Prog Neurobiol. 1996;49:455-479.
4. Fantegrossi WE, Harrington AW, Kiessel CL, Eckler JR, Rabin RA, Winter JC, et al. Hallucinogen-like actions of 5-methoxy- N,N-diisopropyltryptamine in mice and rats. Pharmacol Biochem Behav. 2006;83:122-129.
5. Nagai F, Nonaka R, Satoh H, Kamimura K. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol. 2007;559:132-137.
6. Sogawa C, Sogawa N, Tagawa J, Fujino A, Ohyama K, Asanuma M, et al. 5-Methoxy-N,N-diisopropyltryptamine (Foxy), a selective and high affinity inhibitor of serotonin transporter. Toxicol Lett. 2007;170:75-82.
7. Bortolozzi A, Diaz-Mataix L, Scorza MC, Celada P, Artigas F. The activation of 5-HT receptors in prefrontal cortex enhances dopaminergic activity. J Neurochem. 2005;95:1597-1607.
8. Ago Y, Nakamura S, Uda M, Kajii Y, Abe M, Baba A, et al. Attenuation by the 5-HT1A receptor agonist osemozotan of the behavioral effects of single and repeated methamphetamine in mice. Neuropharmacology. 2006;51:914-922.
9. 1A-receptors. Prog Neurobiol. 2007;81:133-178.
10. Salomon L, Lanteri C, Glowinski J, Tassin JP. Behavioral sensitization to amphetamine results from an uncoupling between noradrenergic and serotonergic neurons. Proc Natl Acad Sci U S A. 2006;103:7476-7481.
11. Rudnick G, Clark J. From synapse to vesicle: the reuptake and storage of biogenic amine neurotransmitters. Biochim Biophys Acta. 1993;1144:249-263.
12. Lester HA, Cao Y, Mager S. Listening to neurotransmitter transporters. Neuron. 1996;17:807-810.
13. --dependent neurotransmitter transporters. Nature. 2005;437:215-223.
14. Yamauchi Y, Izumi T, Unemura K, Uenishi Y, Nakagawa T, Kaneko S. Acceleration of serotonin transporter transport-associated current by 3,4-methylenedioxymethanphetamine (MDMA) under acidic conditions. Neurosci Lett. 2007;428:72-76.
15. Battaglia G, Brooks BP, Kulsakdinun C, De Souza EB. Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol. 1988;149:159-163.
16. Gramsbergen JB, Cumming P. Serotonin mediates rapid changes of striatal glucose and lactate metabolism after systemic 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") administration in awake rats. Neurochem Int. 2007;51:8-15.
17. Pierce RC, Kalivas PW. A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res Rev. 1997;25:192-216.
18. Gael H, Judith H, Joram F, Christian AH. Expression of sensitization to amphetamine and dynamics of dopamine neurotransmission in different laminae of the rat medial prefrontal cortex. Neuropharmacology. 2001;40:366-382.
19. Robinson TE, Jurson PA, Bennett JA, Bentgen KM. Persistent sensitization of dopamine neurotransmission in ventral striatum (nucleus accumbens) produced by prior experience with (+)-amphetamine: a microdialysis study in freely moving rats. Brain Res. 1988;462:211-222.
20. Vanderschuren LJ, Kalivas PW. Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: a critical review of preclinical studies. Psychopharmacology. 2000;151:99-120.
21. Maeda T, Fukazawa Y, Shimizu N, Ozaki M, Yamamoto H, Kishioka S. Electrophysiological characteristic of corticoaccumbens synapses in rat mesolimbic system reconstructed using organotypic slice cultures. Brain Res. 2004;1015:34-40.
22. Stoppini L, Buchs PA, Muller DA. A simple method for organotypic cultures of nervous tissue. J Neurosci Methods. 1991;37:173-182.
23. Fallon JH, Moore RY. Catecholamine innervation of basal forebrain. IV. Topography of the dopamine projection to the basal forebrain and striatum. J Comp Neurol. 1978;180:545-580.
24. Sesack SR, Deutch AY, Roth RH, Bunney BS. Topographical organization of the efferent projections of the medial prefrontal cortex in rat: an anterograde tract-tracing study with Phaseolus vulgaris leucoagglutinin. J Comp Neurol. 1989;290:213-242.
25. Wolf ME. The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants. Prog Neurobiol. 1998;54:679-720.
26. White FJ, Wang RY. Electrophysiological evidence for A10 dopamine autoreceptor sensitivity following chronic damphetamine treatment. Brain Res. 1984;309:283-292.
27. Ohmori T, Abekawa T, Muraki A, Koyama T. Competitive and noncompetitive NMDA antagonists block sensitization to methamphetamine. Pharmacol Biochem Behav. 1994;48:587-591.
28. Wolf ME, Dahlin SL, Hu XT, Xue CJ, White K. Effects of lesions of prefrontal cortex, amygdala, or fornix on behavioral sensitization to amphetamine: comparison with N-methyl-D-aspartate antagonists. Neuroscience. 1995;69:417-439.
29. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Rev. 2003;55:463-508.
30. Cole JC, Sumnall HR. The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA). Neurosci Biobehav Rev. 2003;27:199-217.
31. Baumgarten HG, Lachenmayer L. Serotonin neurotoxins - past and present. Neurotoxic Res. 2004;6:589-614.
32. Sprague JE, Everman SL, Nichols DE. An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. Neurotoxicology. 1998;19:427-441.
33. Breier JM, Bankson MG, Yamamoto BK. L-tyrosine contributes to (+)-3,4-methylenedioxymethamphetamine-induced serotonin depletions. J Neurosci. 2006;26:290-299.
34. Williams MT, Herring NR, Schaefer TL, Skelton MR, Campbell NG, Lipton JW, et al. Alterations in body temperature, corticosterone, and behavior following the administration of 5-methoxydiisopropyltryptamine ("foxy") to adult rats: a new drug of abuse. Neuropsychopharmacology. 2007;32:1404-1420.